Lgals4 Antibody

What is the optimal sample preparation protocol for LGALS4 antibody applications in different experimental techniques?

For optimal results with LGALS4 antibodies across different applications, specific sample preparation protocols are recommended:

Western Blot (WB):

• Use fresh tissue lysates or cell lines with known expression (HT-29, COLO 205, T84, human colon tissues)

• Recommended positive controls: Jurkat, HL-60, HCT116, mouse colon, or LGALS4 transfected 293T lysate

• Perform under reducing conditions with appropriate immunoblot buffer

• Dilution ranges: 1:1000-1:10000 depending on the specific antibody

Immunohistochemistry (IHC):

• For formalin-fixed paraffin-embedded tissues, antigen retrieval is crucial

• Use TE buffer pH 9.0 as primary recommendation for antigen retrieval

• Alternative: citrate buffer pH 6.0 may be used if needed

• Human colon tissue, human colon cancer tissue, and human stomach cancer tissue serve as effective positive controls

• Dilution ranges typically between 1:50-1:5000

Immunofluorescence (IF):

• For paraffin sections (IF-P): Use 1:200-1:800 dilution with human colon cancer tissue as positive control

• For cell culture (IF/ICC): 1:200-1:800 dilution with HT-29 cells as positive control

How should LGALS4 antibodies be stored to maintain optimal reactivity?

For maximum stability and functionality of LGALS4 antibodies:

• Store at -20°C in the provided buffer (typically PBS with 0.02% sodium azide and 50% glycerol, pH 7.3)

• Antibodies are stable for one year after shipment when stored properly

• Aliquoting is generally unnecessary for -20°C storage

• Avoid repeated freeze/thaw cycles to prevent degradation

• Centrifuge briefly prior to opening the vial to collect solution at the bottom

• For reconstituted lyophilized antibodies, reconstitute in 10mM PBS (pH 7.4) to a concentration of 0.1-1.0 mg/mL, do not vortex

What are the expected expression patterns of LGALS4 in normal tissues versus cancerous tissues?

LGALS4 exhibits distinct expression patterns that researchers should be aware of when designing experiments:

Normal tissue expression:

• Primarily expressed in epithelial cells throughout the gastrointestinal tract

• Specific locations include antrum, ileum, colon, and rectum

• Expression restricted to small intestine, colon, and rectum

• Not typically found in healthy pancreas

Cancer tissue expression patterns:

• Significantly underexpressed in colorectal cancer compared to normal tissues

• Approximately 3-fold decrease observed in CRC compared to normal tissues

• Aberrantly induced in cystic tumors of the human pancreas and in PDAC

• Also aberrantly induced in breast and colorectal cancers

• LGALS4 expression correlates with reduced lymph node metastasis in pancreatic cancer patients

How does LGALS4 expression influence cancer progression, and what experimental designs best capture these effects?

Recent research demonstrates complex roles of LGALS4 in cancer progression that require nuanced experimental approaches:

Experimental design recommendations:

• Cell proliferation assays: LGALS4 overexpression results in ~50% decrease in colorectal cancer cell proliferation

• Apoptosis assays: LGALS4 overexpression leads to ~2-fold increase in apoptosis and enhances 5-FU-induced apoptosis

• Glycolysis measurement: Measure glucose uptake, lactate production, and expression of glycolysis-related genes in LGALS4-overexpressing cells

• Migration/invasion assays: Required to assess correlation between LGALS4 expression and reduced migratory/invasive behavior

• β-catenin signaling analysis: Combine LGALS4 overexpression with β-catenin inhibitors (e.g., XAV-939) to assess synergistic effects

Research findings:

• LGALS4 overexpression inhibits CRC cell growth, induces cell cycle arrest, and enhances chemotherapy-induced apoptosis

• LGALS4 inhibits aerobic glycolysis and reduces glucose-dependent activity in CRC cells

• High LGALS4 expression correlates with reduced lymph node metastasis in pancreatic cancer patients:

  • 80% of patients without lymph node metastasis (N0) had high LGALS4 expression

  • 70% of patients with lymph node metastasis (N1) had low LGALS4 expression (P=0.025)

• Patients with low LGALS4 expression had significantly higher lymph node ratio (LNR) than those with high expression

What mechanisms underlie LGALS4's role in immune modulation, and how can these be investigated experimentally?

LGALS4 exhibits dual immunomodulatory functions that require specific experimental designs:

Methodological approaches:

• T-cell apoptosis assays: Use coculture systems with extracellular LGALS4 to assess T-cell apoptosis rates

• Glycosylation binding studies: Investigate LGALS4 binding to N-glycosylation residues on T-cell surface proteins (particularly CD3ε/δ)

• Single-cell RNA sequencing: To identify alterations in immune cell populations within tumor microenvironment in response to LGALS4 modulation

• Immune infiltration analysis: Using deconvolution methods like TIMER to evaluate abundance of different immune cell types

Key research findings:

• Extracellular LGALS4 induces apoptosis in T cells by binding N-glycosylation residues on CD3ε/δ

• LGALS4 modulation affects myeloid compartment and cancer-associated fibroblast (CAF) subtypes

• Reduced LGALS4 expression associates with:

  • Higher proportion of myofibroblastic CAFs

  • Reduced numbers of inflammatory CAFs

  • Higher proportions of M1 macrophages, T cells, and antigen-presenting dendritic cells

• LGALS4 plays a pivotal role in pancreatic cancer tumor-mediated immune suppression

What are the recommended validation strategies to confirm LGALS4 antibody specificity?

Rigorous validation is essential for reliable LGALS4 antibody-based experiments:

Comprehensive validation approach:

• Positive control selection: Use tissues/cells with known high expression:

  • HT-29 cells, human ileum tissue, human colon tissue for human studies

  • Mouse colon, mouse small intestine, rat colon tissue for rodent studies

• Western blot validation:

  • Expected molecular weight: 34-36 kDa

  • Verify absence of non-specific bands

  • Include knockout/knockdown controls where possible

• Cross-reactivity testing:

  • Test against related galectins (especially galectin-1, -3, -7, -8) to ensure specificity

  • Consider testing predicted reactivity in other species: Dog (80%), Pig (81%), Rabbit (88%)

• Orthogonal validation:

  • Correlate protein detection with mRNA expression data (RNAseq)

  • Compare antibody detection patterns with in situ hybridization

  • Use multiple antibodies targeting different epitopes of LGALS4

How should researchers interpret contradictory findings related to LGALS4's role in different cancer types?

LGALS4 exhibits context-dependent functions that require careful experimental design and interpretation:

Methodological considerations:

• Separate intracellular vs. extracellular functions: The localization of LGALS4 significantly impacts its function

• Consider cancer type specificity: Design experiments to account for tissue-specific effects

• Distinguish between correlation and causation: Use both observational studies and mechanistic investigations

• Account for LGALS4 expression levels: Quantitative analysis rather than binary presence/absence

Contradictory findings explained:

• In pancreatic cancer: LGALS4 shows dual effects - suppressing migration but potentially promoting immune evasion through T-cell apoptosis

• In colorectal cancer: Consistently reported as downregulated and functioning as a tumor suppressor

• Different experimental approaches may capture different aspects of LGALS4 biology

What are the optimal experimental conditions for investigating LGALS4's interaction with carbohydrate structures?

LGALS4 contains two carbohydrate recognition domains (CRDs) that require specific experimental approaches:

Recommended methodologies:

• Hemagglutination assays:

  • Use rabbit erythrocytes in a serial dilution format

  • Minimal effective concentration determined at approximately 3.187μg/mL

  • Perform in U or V-bottom shaped 96-well microtiter plates

  • Use 0.9% sodium chloride as diluent

  • Incubate for 3 hours at room temperature

• Glycan binding analysis:

  • Study binding to β-galactose-containing oligosaccharides

  • Evaluate binding to N-glycosylation residues on specific proteins (e.g., CD3ε/δ)

  • Consider both CRDs in experimental design as they may have different binding preferences

• Functional assays:

  • Combine carbohydrate binding studies with functional readouts

  • Assess how specific glycan interactions affect cell adhesion, migration, or immune cell function

How can single-cell analysis techniques be leveraged to understand LGALS4's role in the tumor microenvironment?

Single-cell approaches provide powerful insights into LGALS4's complex functions within heterogeneous tissues:

Experimental design recommendations:

• Single-cell RNA sequencing:

  • Compare immune cell populations and transcriptional profiles in tumors with high vs. low LGALS4 expression

  • Identify cell subpopulations affected by LGALS4 modulation

  • Research has revealed LGALS4 expression affects myeloid compartment and CAF subtypes

• Spatial transcriptomics/proteomics:

  • Map LGALS4 expression patterns relative to immune cell populations

  • Correlate with markers of inflammation, fibrosis, and tumor progression

• CyTOF/flow cytometry:

  • Profile immune cell populations

  • Quantify LGALS4 binding to specific immune cell subsets

  • Assess impact on immune cell activation status

Key findings to consider:

• Reduced LGALS4 expression associates with altered tumor microenvironment:

  • Higher proportion of myofibroblastic CAFs

  • Reduced inflammatory CAFs

  • Higher proportions of M1 macrophages, T cells, and antigen-presenting dendritic cells

• These changes may contribute to LGALS4's role in modulating anti-tumor immunity

What are the most promising therapeutic strategies targeting LGALS4 based on recent research?

Recent findings suggest several potential therapeutic approaches:

Target validation approaches:

• For pancreatic cancer: Target extracellular LGALS4 to overcome immunosuppression

• For colorectal cancer: Enhance LGALS4 expression to leverage tumor-suppressive properties

• Combined approach: Target LGALS4 in combination with glycolysis inhibitors or β-catenin pathway modulators

Experimental considerations:

• Patient stratification: Consider LGALS4 expression levels for precision medicine approaches

• Delivery methods: Develop strategies for tissue-specific targeting

• Combination therapies: Test LGALS4-targeting approaches with chemotherapy, as LGALS4 overexpression enhances 5-FU sensitivity

Research evidence:

• LGALS4 overexpression enhances 5-FU-induced apoptosis in CRC cells

• Extracellular LGALS4 is identified as "a promising drug target for overcoming immunosuppression in PDAC"

• LGALS4's role in β-catenin signaling suggests potential synergistic approaches with pathway inhibitors

• Context-dependent functions require careful therapeutic design based on cancer type and stage

What LGALS4 co-expression patterns are significant for experimental design and interpretation?

Understanding the gene networks and protein interactions associated with LGALS4 can improve experimental design:

Methodological approaches:

• Co-expression analysis: Examine correlations between LGALS4 and other genes in relevant datasets

• Protein-protein interaction studies: Identify direct binding partners that may influence LGALS4 function

• Pathway analysis: Map LGALS4 to cellular pathways to identify potential functional relationships

Significant interactions:

• β-catenin pathway: LGALS4 affects glycolysis partly through β-catenin signaling

  • LGALS4's effects on glycolysis-related genes are enhanced by β-catenin inhibitor XAV-939

• Glycolysis enzymes: Monitor key glycolysis-related genes when studying LGALS4 function

• Immune receptors: LGALS4 binds to glycosylated immune cell receptors, particularly CD3ε/δ on T cells